Table 5 Changes in pharmacological treatment rates over the study period
From: Improving organisational systems for diabetes care in Australian Indigenous communities
Treatment | Baseline | Year 1 | Year 2 | Risk Ratios (95% CI)†Year 1 vs baseline | Risk Ratios (95% CI)†Year 2 vs baseline |
|---|---|---|---|---|---|
Any insulin use | 10% (29/295) | 11% (29/253) | 10% (24/252) | 1.17 (0.96, 1.40) | 0.97 (0.79, 1.19) |
Oral hypoglycaemic agents only | 69% (203/295) | 72% (181/253) | 71% (180/252) | 1.05 (0.83, 1.21) | 1.08 (0.92, 1.20) |
Hypertension on treatment | 78% (112/143) | 89% (111/125) | 75% (119/159) | 1.16 (1.04, 1.22) | 0.96 (0.79, 1.09) |
Albuminuria on ACE inhibitor | 85% (129/151) | 85% (124/146) | 72% (114/158) | 1.02 (0.86, 1.11) | 0.87 (0.69, 1.00) |
Hyperlipidemia on statin | 71% (99/140) | 83% (128/154) | 67% (98/146) | 1.34 (1.18, 1.39) | 0.93 (0.75, 1.09) |
Coronary heart disease/stroke on aspirin | 56% (32/57) | 60% (30/50) | 70% (30/43) | 1.00 (0.46, 1.47) | 1.30 (0.85, 1.59) |
Aspirin use among diabetes patients without cardiovascular events but with one or more other cardiovascular risk factors* | 31% (53/173) | 55% (91/165) | 55% (101/184) | 2.90 (2.11, 3.15) | 2.21 (1.67, 2.62) |